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Abstract
Objective Effective short-term outcomes have been well doc-
umented for trigeminal neuralgia (TN) patients treated with
Gamma Knife radiosurgery (GKRS) with reported success
rates of 70–90 % with median follow-up intervals of
19–75 months. Fewer series, however, have described uni-
form long-term follow-up data. In this study, we report our
long-term institutional outcomes in patients treated with
GKRS after a minimum follow-up of 36 months.
Methods Thirty-six consecutive patients with medically in-
tractable TN received a median radiation dose of 45 Gy ap-
plied with a single 4-mm isocenter to the affected trigeminal
nerve. Follow-up data were obtained by clinical examination
and telephone questionnaire. Outcome results were catego-
rized based on the Barrow Neurological Institute (BNI) pain
scale with BNI I–III considered to be good outcomes and BNI
IV–V considered as treatment failure. BNI facial numbness
score was used to assess treatment complications.
Results The incidence of early pain relief was high (80.5 %)
and relief was noted in an average of 1.6 months after treat-
ment. At minimum follow-up of 3 years, 67 % were pain free
(BNI I) and 75 % had good treatment outcome. At a mean last
follow-up of 69 months, 32 % were free from any pain and
63 % were free from severe pain. Bothersome posttreatment
facial numbness was reported in 11 % of the patients. A
statistically significant correlation was found between age
and recurrence of any pain with age >70 predicting a more
favorable outcome after radiosurgery.
Conclusion The success rate of GKRS for treatment of
medically intractable TN declines over time with 32 %
reporting ideal outcome and 63 % reporting good out-
come. Patients older than age 70 are good candidates
for radiosurgery. This data should help in setting realis-
tic expectations for weighing the various available treat-
ment options.
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Introduction
Trigeminal neuralgia (TN), also known as tic doloreaux, is a
debilitating pain condition characterized by agonizing,
paroxysmal, and lancinating pain [1]. First-line treat-
ment includes anticonvulsant and antidepressant, but this
often fails to provide pain relief and is associated with
various side effects, leading patients to seek other treat-
ments options [1]. Second-line treatment modalities are
given to patients whose symptoms are intractable or who
cannot tolerate medication. These include surgical procedures
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such as microvascular decompression, and ablative proce-
dures such as percutaneous balloon microcompression, radio-
frequency rhizotomy, glycerol rhizolysis, and Gamma Knife
radiosurgery (GKRS). The short-term outcomes of patients
treated with GKRS are well described [2]. Initial publications
with the GKRS system at short median follow-up of approx-
imately 2 years report pain relief outcomes in 70–90% of their
patients and pain-free status in 20–60 % [3–7]. As longer
series with median follow-up of 19–75 months started to
emerge, pain relief rates ranging from 65 to 85 % were
reported [5, 8–10]. However, failure to exclude patients with
short-term follow-up in long-term analysis muddied the inter-
pretation and prevented a clear understanding of longevity of
GKRS's effectiveness in controlling TN pain. More recently, a
few studies have examined long-term follow-up of GKRS in
controlling pain with variable outcomes [11–15]. Here, we
present our long-term institutional outcomes of GK in the
treatment of TN by restricting our analysis to include only




After institutional review board approval, patient demograph-
ic characteristics, clinical presentation, treatment history, and
the radiosurgical modality were retrospectively reviewed.
Patients were also followed up by a telephone question-
naire that was conducted by a medical resident and a medical
student who were not involved in treatment. Patients were
questioned about the time to the onset of pain relief, the degree
of pain relief, and treatment complications. Based on the
Barrow Neurological Institute (BNI) score for TN, we classi-
fied pain relief after treatment into five grades. A BNI I score
corresponded to complete pain relief without medications;
BNI II score, some pain but not requiring medications; BNI
III score, some pain but adequately controlled with medica-
tions; BNI IV score, some pain not adequately controlled with
medication; and BNI V score, severe pain or no pain relief.
The BNI facial numbness score was used to assess complica-
tions. A BNI I score corresponded to no facial numbness; BNI
II score, mild facial numbness, not bothersome; BNI III, facial
numbness somewhat bothersome; and BNI IV score, facial
numbness, very bothersome.
Between September 2002 and June 2010, 81 patients with
TN underwent GKRS at our clinic. Indications for GKRS
included medically intractable pain refractory to standard
medications, refusal of invasive procedures, or failure of pre-
vious invasive procedures. Among them, we retrospectively
reviewed the medical records of patients with TN undergoing
GKRS treatment that had a minimum follow-up of 36months.
Ten patients had died prior to their 36 months follow-up.
Fourteen patients were lost to follow-up and were lost to
follow-up and on whom we were unable to obtain accurate
contact information. Five patients had received GKRS treat-
ment twice and were excluded. Two patients had bilateral
disease and were excluded. Eleven patients refused to partic-
ipate in the survey and adequate follow-up could not be
obtained on the remaining 20 patients despite valid phone
numbers and multiple attempts. Three patients were retreated
but results of GKS retreatment were not included in this
analysis. Rather, our report presents the results of single
GKS treatment for patients with TN when using a standard
treatment algorithm. A total of 36 patients were included in
the final analysis with a mean follow-up of 69 months (range
36–246 months). A summary of patient characteristics is
provided in Table 1. None of the patients included in the final
analysis had multiple sclerosis.
Radiosurgery technique
All patients were treated on the 201-source 60Co Gamma
Knife unit, model 4C, manufactured by Elekta instruments
(Elekta, Norcross, Georgia). Treatment planning was per-
formed jointly by a radiation oncologist, neurosurgeon, and
medical physicist for all cases. After induction of local anes-
thesia, the Leksell Model G stereotactic coordinate frame was
affixed to the head of each patient, and contrast enhanced MR
imaging was performed to visualize and target the trigeminal
nerve root entry zone. As a planning tool, the Leksell Gamma
Plan System (Elekta) was used. A single 4-mm isocenter was
placed adjacent to the trigeminal nerve root entry zone. The
median peripheral dose was 45 Gy with a range of maximum
dose between 80 and 90 Gy delivered to the involved trigem-
inal nerve root entry zone. A plugging pattern typically
Table 1 Clinical demo-
graphic characteristics in
36 patients with medi-
cally intractable trigemi-





Male 14 (39 %)
Female 22 (61 %)
Mean age (range) 71 (29–97)
Prior surgery 4 (11 %)




V2 17 (47 %)
V3 11 (30.5 %)
V2,3 6 (17 %)
V1,2,3 2 (5.5 %)
Side of pain
Right 15 (42 %)
Left 21 (58 %)
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blocking 32 sources was used so that the surface of the
brainstem was irradiated at no greater than the 20 % isodose
line for any patient.
Statistical analysis
Treatment outcomes were assessed by patient self-reports of
pain control and medication usage at last follow-up. A pain-
free outcome was defined as BNI pain score I and pain relief
or good outcome was regarded as maintaining a BNI pain
score IIIa or better without requiring further surgery.
Treatment failure was defined as pain returning to a BNI level
of IV or V, or the patient undergoing an invasive surgical
procedure due to uncontrolled pain. A recurrence was defined
as a relapse to a previous lower level after attainment of any
higher level of pain relief. Patients reported the time interval
for a response and pain recurrence after GKRS. The date of
treatment failure was considered to be the date at which pain
relief became a BNI IVor V score.
Time to BNI class IV to V pain relapse was calculated with
the Kaplan–Meier method. Log rank tests were performed to
determine statistical differences between pain relapse curves.
We conducted a univariate analysis of several factors hypoth-
esized to influence or predict successful treatment, using Cox
regression analysis: age, gender, side of pain, duration of
symptoms, new facial numbness. A p value <0.05 was ac-
cepted as statistically significant. All statistical calculations
were performed using SPSS software, version 13.0 (SPSS,
Inc., Chicago, IL, USA).
Results
Pain relief after GKRS
The mean time from GKRS to pain improvement was
1.6 months (range, 1 day–6 months). Of those patient that
experienced immediate pain relief (29 or 80.6%), the majority
(27 or 75 %) described an early pain response to treatment
within the first 2 months after GKRS, whereas two (5.5 %)
patients reported symptoms relief after 2 months. Seven pa-
tients (19 %) reported no pain response. The median time
to recurrence of any symptoms was 46 months (range,
6–116 months). Of the 29 patients that experienced pain
relief, 17 (58.6 %) did not have any pain recurrence (BNI I),
while the remaining 12 (41.4 %) had some return of some pain
(BNI ≥2). Results of Kaplan–Meier analysis of response time
after GKRS are displayed in Fig. 1. At median follow-up of
5 years, actuarial freedom from any pain recurrence (BNI ≥2)
is 40 %.
At last follow-up, 26 (72.2 %) patients had good treatment
outcome (BNI I, II, or III) and 10 patients (27.8 %) had
treatment failure. The 10 patients with treatment failure
included the seven patients who did not have any response to
treatment. Kaplan–Meier analysis shows an actuarial rate
freedom from severe pain of 63 % at mean last follow-up of
69 months (Fig. 1b). The patient responses at last follow-up,
as determined using the BNI pain intensity scoring system, are
listed in Table 2. At last follow-up, 14 (39 %) of the patients
Fig. 1 a Kaplan–Meier curve for time from Gamma Knife radiosurgery
(GKRS) and freedom from any pain (BNI I). b Kaplan–Meier curve for
time from Gamma Knife radiosurgery (GKRS) to Barrow Neurologic
Institute (BNI) class IV to V pain relapse (i.e., freedom from severe pain)
Table 2 Pain response
(top 5 rows) and devel-
opment of facial numb-
ness post treatment (bot-




BNI pain intensity scale
BNI I 14 (39)
BNI II 3 (8)
BNI III 8 (22)
BNI IV 8 (22)
BNI V 3 (8)
BNI facial numbness score
BNI I–II 32 (89)
BNI III 0 (0)
BNI IV 4 (11)
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had no pain and no medications (BNI I) with a median time of
maintaining a BNI I pain score of 46 months (range, 36–
77 months). A summary of pain outcomes at last follow-up
is listed in Table 3.
Treatment-related complications
The majority of the patients (26 or 72.2 %) did not experience
any post-treatment facial numbness. Two patients (16.7 %)
reported mild facial numbness that was not bothersome. Very
bothersome facial numbness (BNI IV) was reported in a total
of four patients (11.1 %) (Table 2). However, all four patients
had good pain treatment outcome with three reporting a post-
treatment BNI pain intensity score of I and one patient
reporting a BNI pain score of II at longest follow-up. All four
had received a treatment dose of 45 Gy. There were no reports
of decreased corneal sensation (dry eye syndrome).
Prognosticators
Univariate analysis for previously published prognosticators of
treatment failure is shown in Table 4. No statistically significant
correlation was found between treatment failure and age, gen-
der, dose, laterality of pain, duration of symptoms, or develop-
ment of new bothersome facial numbness. There was, however,
a statistically significant difference between age and recurrence
or persistence of any pain (BNI >1) and age (p =0.02). Patients
older than 70 reported significantly better freedom from any
pain compared with those less than 70 years of age.
Discussion
In their large series, Kondziolka et al. [2] and Régis et al. [7]
reported that GKRS was a safe and effective alternative treat-
ment to surgical procedures in the treatment of medically
intractable TN. However, treatment outcomes and treatment-
related complication rates have varied according to follow-up
period, time for assessment of pain outcome, and different
pain scores. In the present study, we report on pain outcome
and side effects using standardized pain scores with a mini-
mum 3-year follow-up to evaluate the long-term results of
GKRS for TN.
Allowing for variability in grading systems among studies,
our results are similar to previously published results [11, 16].
The incidence of early pain relief was high (80.5 %) in our
series. Pain relief was noted an average of 1.6 months after
treatment. This time frame is consistent with previously pub-
lished data [11, 16]. At our institution, we have therefore taken
a similar approach to others by discussing further treatment
options in which no degree of pain relief has been achieved in
6 months.
Our series is one of few to include only longer term follow-
up of patients undergoing GKS for TN. An increasing body of
literature suggests that the beneficial effect of stereotactic
radiation on TN diminishes with time. At minimum follow-
up of 3 years, 67 % were pain free (BNI I) and 75 % had good
treatment outcome. At a mean last follow-up of 69 months,
32 % were free from any pain and 63 % were free from severe
pain. Our results are strikingly similar to previously reported
long-term analysis of TN pain outcomes. In a small series with
minimum follow-up of 3 years, Park et al. [13] reported 17 %
pain-free outcomes and 65 % with good pain outcome.
Sheehan et al. [9] presented a subgroup of 39 patients (mini-
mum 3-year follow-up) in which 70% reported pain relief and
34 % reported an “ideal” outcome (BNI grade I). At a mini-
mum follow-up of 36 months and an average follow-up of
48 months, Riesenburger et al. [11] reported on 53 patients
with 58.5 % of patients experiencing good treatment outcome
and 32.1 % of patients with pain-free outcome. In a more
recently published series, Lee et al. [15] reported 27.3%BNI I
and II outcomes and 68 % good outcomes when data from 40





Freedom from any pain (n=36) 67 32
Freedom from any pain recurrence
in responders (n =29)
83 40
Freedom from severe pain or good
treatment outcome (n =36)
75 63
Table 4 Summary of various prognosticators and development of treat-






No of patients 25 (69.4 %) 11 (30.6 %) 0.03
Gender
Male 16 6 0.87
Female 9 5
Age
≥70 years 15 4 0.34
<70 years 10 7
Side of pain
Right 9 6 0.50
Left 16 5
Duration of symptoms
>18 months 5 5 0.20
<18 months 16 4
Dose
40 Gy 7 5 0.52
45 Gy 18 6
New bothersome facial numbness 4 0 0.41
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patients with minimum of 60-months follow-up and an aver-
age follow-up of 92.2 months were analyzed. Finally, in one
of the largest series, Little and associates [12] reported actu-
arial data on 136 patients with a minimum follow-up duration
of 4 years. At a mean follow-up of 6.3 years, they report 32 %
of their patients being pain free off and off medication at
7 years and 83 % with good treatment outcomes, although
they did include retreatment of patients [12]. In our series, we
had lower response rates than those of Little et al. but results of
retreatment were not included, whichwewould have expected
to have increased the rate of overall successful pain relief.
Our incidence of new-onset facial numbness at 11%was in
accordance with previously published incidences. The report-
ed incidence of facial numbness has ranged from 6 to 37 %
[2, 5, 7, 9, 11, 16–18] with most series reporting new-onset
numbness in ~10% of treated patients. Similar to Riesenburger
et al. [11], our series did not reveal any statistically significant
correlation between known prognosticators such as age, gen-
der, side of pain, duration of pain, or new-onset facial numb-
ness and development of treatment failure at last follow-up.
However, a statistically significant correlation was found
between age and recurrence of any pain with age >70 predicting
a more favorable outcome radiosurgery. In their series examin-
ing long-term pain outcomes of TN, Han et al. [14] reported a
similar correlation between older age >70 and favorable out-
come in terms of pain recurrence after radiosurgery. The issue of
age has been controversial in the literature as other series have
reported a prognostic association between younger age and
achieving and maintaining pain relief [8, 19]. Both of these
studies, however, have been based on shorter follow-up period
after radiosurgery. A correlation between history of prior abla-
tive surgery and pain outcomes has long been established for TN
pain recurrence after radiosurgery [1]. Given the low number of
events in our series with only four patients having had under-
gone previous ablative procedures, that correlation could not be
tested in our current study. Whether that could have biased our
data in favor of a positive correlation between older age and pain
recurrence after radiosurgery remains an uncertain question that
needs to be addressed in larger sample sized studies.
Finally, although the median peripheral dose of 45 Gy that
our institution has adopted is higher than the currently recom-
mended dose (40 Gy) necessary to provide pain relief while
avoiding toxicity [19, 20], we did not find a correlation
between dose and either development of treatment failure at
last follow-up or development of new bothersome facial
numbness. Our analysis could have been underpowered in
detecting a dose–outcome correlation, especially since the rate
of trigeminal nerve dysfunction has been reported to decline
with the increased follow-up duration [20]. Variations in other
technical nuances of radiosurgery between institutions such as
volume of nerve treated and anatomical location of the target
(and hence the dose to the intraaxial portion of fifth nerve
fibers in the brainstem) could have also confounded the
impact of “high dose” (90 Gy) on both the probability of
long-term pain control and fifth nerve dysfunction [21].
Conclusion
GKRS is a safe, effective, and minimally invasive treatment
modality for patients with medically intractable TN or those
who are ineligible or refuse open surgery. Our results demon-
strate that a single GKS treatment is associated with good
outcomes in nearly 60 % of patients in an average follow-up
period of approximately 6 years. While most pain recurrence
develops within 6 months of treatment, treatment failure may
still manifest years later. Our results also suggest that patients
>70 presenting with medically intractable TN are good can-
didates for radiosurgery. The small sample size and retrospec-
tive nature of our study design limit the power of our outcome
observations. Additionally, although pain intensity and numb-
ness scales are validated tools for the quantification of pain
and numbness, they are subjective outcome measures because
they are dependent on personal interpretations and variation.
The results of this study should, however, help clinicians
provide important information to patients so they can have
realistic expectations and be able to weigh the risks and
benefits relative to the various available treatment options.
Ethical statement Institutional Review Board exemption from a full
board review was obtained prior to research commencement. This article
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Statement of informed consent Prior to the phone interview, the
following are telephone consent script for retrospective review of effica-
cy, treatment outcomes, and toxicity of Gamma Knife radiosurgery for
treatment of trigeminal neuralgia. This consent was standardized every
time that a patient is contacted.
After the investigator introduces himself/herself, the purpose of the
phone interview is stated as research aimed at gaining more knowledge
about GammaKnife treatment outcomes. The participant is then asked for
willingness to participate in the phone interview. If they accept then the
investigator proceeds with the survey as detailed under the Methods
section of the manuscript. If they decline, then the participant is thanked
for their time and the phone call is terminated.
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